![A) Overall response rate by cohorts. ORR indicates a response of PR or... | Download Scientific Diagram A) Overall response rate by cohorts. ORR indicates a response of PR or... | Download Scientific Diagram](https://www.researchgate.net/publication/348022825/figure/fig1/AS:1093215843299328@1637654376054/A-Overall-response-rate-by-cohorts-ORR-indicates-a-response-of-PR-or-better-ORR.png)
A) Overall response rate by cohorts. ORR indicates a response of PR or... | Download Scientific Diagram
![Abbreviations: CR, complete response; ORR, objective response rate; PR,... | Download Scientific Diagram Abbreviations: CR, complete response; ORR, objective response rate; PR,... | Download Scientific Diagram](https://www.researchgate.net/publication/320150987/figure/fig2/AS:865479920984064@1583357901551/Abbreviations-CR-complete-response-ORR-objective-response-rate-PR-partial-response.png)
Abbreviations: CR, complete response; ORR, objective response rate; PR,... | Download Scientific Diagram
![Figure 4 | Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence Figure 4 | Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence](https://static-02.hindawi.com/articles/jo/volume-2012/417673/figures/417673.fig.004.jpg)
Figure 4 | Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence
![Response rate of anticancer drugs approved by the Food and Drug Administration based on a single-arm trial | BMC Cancer | Full Text Response rate of anticancer drugs approved by the Food and Drug Administration based on a single-arm trial | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-022-09383-w/MediaObjects/12885_2022_9383_Fig1_HTML.png)
Response rate of anticancer drugs approved by the Food and Drug Administration based on a single-arm trial | BMC Cancer | Full Text
![Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma | Business Wire Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma | Business Wire](https://mms.businesswire.com/media/20170907005441/en/610835/5/Melanoma_Data_Chart_.jpg)